| Most volume traded stocks | Today's change | Price |
|---|---|---|
| 39.2 (1.89%) | ₹2113.3 | |
| 2537.33 (14.16%) | ₹20457 | |
| -9.56 (-0.71%) | ₹1336.9 | |
| -7.44 (-0.75%) | ₹985.25 | |
| 0.75 (1.27%) | ₹59.99 |
| Stocks touching upper circuit | Today's change | Price |
|---|---|---|
| 300 (20%) | ₹360 | |
| 141 (20%) | ₹169.2 | |
| 33.41 (19.99%) | ₹40.09 | |
| 100.8 (19.99%) | ₹120.95 | |
| 20.36 (19.99%) | ₹24.43 |
Titan Company Ltd
View Details
₹3,813.50
2.39%▲
Earnings Miss
Market Sentiment
Key Highlight
The lower-than-expected growth in the jewellery segment and subsequent drop in share price indicate potential challenges ahead for Titan, affecting investor confidence and future valuations.
View Quick Insights
28 Analysts say
BUY
Net profit rises 12% to Rs 27.5 crore, with revenue increasing 8.4% to Rs 3,032 crore.
Apollo Micro Systems Reports Strong Financial Growth
Apollo Micro Systems reports 98.2% increase in net profit to Rs 31.1 Cr and 40.2% revenue growth to Rs 225 Cr.
Chalet Hotels Reports Strong Revenue and Profit Growth
Chalet Hotels reports a revenue increase of 95% to Rs 735 crore and a net profit of Rs 155 crore, recovering from a loss.
RBL Bank Sees Profit Rise Amid Stake Sales
Emirates NBD Bank proposes an open offer to acquire 26% stake in RBL Bank at ₹280 per share, totaling ₹11,636 crore.
Gujarat Pipavav Port Sees Significant Profit Growth
ABFRL Reports Revenue Growth and Narrowed Loss
Aditya Birla Fashion & Retail reports 13% YoY revenue growth in Q2 FY26, driven by luxury and ethnic wear segments.
Deepak Fertilisers Reports Stable Profit and Revenue Growth
Deepak Fertilisers reports net profit of Rs 214 crore, revenue up 9% YoY to Rs 3,005.8 crore.
Blue Star Reports Profit and Revenue Growth
Blue Star reports a 2.8% increase in net profit to Rs 98.78 crore and a 9.3% rise in revenue to Rs 2,422.4 crore.
Indian Hotels Reports Mixed Q2 Results and Outlook
Indian Hotels Company reported a 12% YoY revenue increase to Rs 2,124 crore and a 15% YoY profit growth to Rs 285 crore, excluding one-time gains.
Marksans Pharma Secures Approval for Cancer Drug
Marksans Pharma's subsidiary Relonchem receives UK MHRA marketing authorization for Exemestane 25mg film-coated tablets for hormone-positive breast cancer treatment.